JOSÉ ÁNGEL
RUIZ ORTEGA
Publicaciones (49) Publicaciones de JOSÉ ÁNGEL RUIZ ORTEGA
2024
-
Automated procedure to detect subtle motor alterations in the balance beam test in a mouse model of early Parkinson’s disease
Scientific Reports, Vol. 14, Núm. 1
2023
-
Efficacy of invasive and non-invasive methods for the treatment of Parkinson's disease: Nanodelivery and enriched environment
International Review of Neurobiology (Academic Press Inc.), pp. 103-143
-
Peripheral CB1 receptor blockade acts as a memory enhancer through a noradrenergic mechanism
Neuropsychopharmacology, Vol. 48, Núm. 2, pp. 341-350
2020
-
Changes in Day/Night Activity in the 6-OHDA-Induced Experimental Model of Parkinson’s Disease: Exploring Prodromal Biomarkers
Frontiers in Neuroscience, Vol. 14
2019
-
Acute L-DOPA administration reverses changes in firing pattern and low frequency oscillatory activity in the entopeduncular nucleus from long term L-DOPA treated 6-OHDA-lesioned rats
Experimental Neurology, Vol. 322
-
Beneficial effects of n-3 polyunsaturated fatty acids administration in a partial lesion model of Parkinson's disease: The role of glia and NRf2 regulation
Neurobiology of Disease, Vol. 121, pp. 252-262
-
Therapeutic potential of cannabinoids as neuroprotective agents for damaged cells conducing to movement disorders
International Review of Neurobiology (Academic Press Inc.), pp. 229-257
2018
-
Análisis estadístico para realizar acciones de mejora en los Trabajos Fin de Grado. Una propuesta para el Grado en Farmacia
REDU: Revista de Docencia Universitaria, Vol. 16, Núm. 2
-
Correction to: Deleterious Effects of VEGFR2 and RET Inhibition in a Preclinical Model of Parkinson’s Disease (Molecular Neurobiology, (2018), 55, 1, (201-212), 10.1007/s12035-017-0733-x)
Molecular Neurobiology
-
Deleterious effects of VEGFR2 and RET inhibition in a preclinical model of Parkinson’s disease
Molecular Neurobiology, Vol. 55, Núm. 1, pp. 201-212
-
Nanodelivery of cerebrolysin and rearing in enriched environment induce neuroprotective effects in a preclinical rat model of Parkinson’s disease
Molecular Neurobiology, Vol. 55, Núm. 1, pp. 286-299
2017
-
Morphological Changes in a Severe Model of Parkinson’s Disease and Its Suitability to Test the Therapeutic Effects of Microencapsulated Neurotrophic Factors
Molecular Neurobiology, Vol. 54, Núm. 10, pp. 7722-7735
2016
-
Buspirone requires the intact nigrostriatal pathway to reduce the activity of the subthalamic nucleus via 5-HT1A receptors
Experimental Neurology, Vol. 277, pp. 35-45
-
Cannabinoids and Motor Control of the Basal Ganglia: Therapeutic Potential in Movement Disorders
CANNABINOIDS IN HEALTH AND DISEASE (INTECH EUROPE), pp. 59-92
-
Chronic L-DOPA administration increases the firing rate but does not reverse enhanced slow frequency oscillatory activity and synchronization in substantia nigra pars reticulata neurons from 6-hydroxydopamine-lesioned rats
Neurobiology of Disease, Vol. 89, pp. 88-100
-
Intranasal administration of chitosan-coated nanostructured lipid carriers loaded with GDNF improves behavioral and histological recovery in a partial lesion model of Parkinson's disease
Journal of Biomedical Nanotechnology, Vol. 12, Núm. 12, pp. 2220-2230
2015
-
Competencias transversales en el Grado en Farmacia: una responsabilidad compartida para los equipos docentes
Evaluación de la Calidad de la Investigación y de la Educación Superior: libro de resúmenes XI FECIES
-
Topographical Distribution of Morphological Changes in a Partial Model of Parkinson’s Disease—Effects of Nanoencapsulated Neurotrophic Factors Administration
Molecular Neurobiology, Vol. 52, Núm. 2, pp. 846-858
2014
-
Buspirone anti-dyskinetic effect is correlated with temporal normalization of dysregulated striatal DRD1 signalling in l-DOPA-treated rats
Neuropharmacology, Vol. 79, pp. 726-737
-
Increased antiparkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson's disease
International Journal of Nanomedicine, Vol. 9, Núm. 1, pp. 2677-2687